Phio Pharmaceuticals Corp./$PHIO

1D1W1MYTD1Y5YMAX

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Ticker
$PHIO
Sector
Health
Primary listing
NASDAQ
Employees
6
Headquarters
King of Prussia, United States
Website
phiopharma.com

PHIO Metrics

BasicAdvanced
$12M
-
-$1.36
0.79
-

PHIO News

AllArticlesVideos

Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Newsfile Corp1 week ago

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Newsfile Corp1 month ago

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Newsfile Corp2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.